•  Persian
    • Persian
    • English
  •   ورود
  • دانشگاه فردوسی مشهد
  • |
  • مرکز اطلاع‌رسانی و کتابخانه مرکزی
    • Persian
    • English
  • خانه
  • انواع منابع
    • مقاله مجله
    • کتاب الکترونیکی
    • مقاله همایش
    • استاندارد
    • پروتکل
    • پایان‌نامه
  • راهنمای استفاده
View Item 
  •   کتابخانه دیجیتال دانشگاه فردوسی مشهد
  • Fum
  • Articles
  • ProfDoc
  • View Item
  •   کتابخانه دیجیتال دانشگاه فردوسی مشهد
  • Fum
  • Articles
  • ProfDoc
  • View Item
  • همه
  • عنوان
  • نویسنده
  • سال
  • ناشر
  • موضوع
  • عنوان ناشر
  • ISSN
  • شناسه الکترونیک
  • شابک
جستجوی پیشرفته
JavaScript is disabled for your browser. Some features of this site may not work without it.

15-Lipoxygenase inhibitors: A patent review

نویسنده:
حمید صادقیان
,
آتنا جباری الم دشت
,
Hamid Sadeghian
,
Atena Jabbari alamdasht
سال
: 2016
چکیده: Introduction: 15-Lipoxygenases (15-LOXes) are a family of iron-containingproteins that have the capability for unsaturated fatty acid peroxidation inanimals and plants. Two types of the enzyme, 15-LOX-1 and 15-LOX-2, havebeen recognized in mammals to have different abilities in the peroxidationof arachidonic acid and linoleic acid. In mammalians, the critical role of thementioned enzymes and their metabolites, hydroxyoctadecadienoic acid(HODE), lipoxins and eoxins, in the formation of inflammation, sensitivities,atherosclerosis and some cancers has been demonstrated.Areas covered: This article reviews relevant publications and patents on 15-LOX inhibitors from the points of view of synthesis and biological activities.Herein, based on the chemical structure and pharmacophore moiety, 15-LOXinhibitors are categorized into heterocyclic, phenolic, allyl and allyloxyderivatives.Expert opinion: It is noteworthy that to date no pharmaceutical productfrom 15-LOX inhibitors has been approved for therapeutic usage. Recently,the role of 15-LOX-1 in obesity, by directly relating 15-LOX-1 expression withthe proliferation and hypertrophy of adipose cells, has been reported. Basedon the role 15-LOX plays in promoting cancer by amplifying PPARγtranscrip-tion activity, however, it can be claimed that 15-LOX inhibitors will bedeemed suitable as chemotherapy agents in the near future
یو آر آی: https://libsearch.um.ac.ir:443/fum/handle/fum/3364236
کلیدواژه(گان): allyl benzenes,allyloxy benzenes,eoxin,heterocyclic compounds,HODE,phenolic

compounds
کالکشن :
  • ProfDoc
  • نمایش متادیتا پنهان کردن متادیتا
  • آمار بازدید

    15-Lipoxygenase inhibitors: A patent review

Show full item record

contributor authorحمید صادقیانen
contributor authorآتنا جباری الم دشتen
contributor authorHamid Sadeghianfa
contributor authorAtena Jabbari alamdashtfa
date accessioned2020-06-06T13:40:03Z
date available2020-06-06T13:40:03Z
date issued2016
identifier urihttps://libsearch.um.ac.ir:443/fum/handle/fum/3364236
description abstractIntroduction: 15-Lipoxygenases (15-LOXes) are a family of iron-containingproteins that have the capability for unsaturated fatty acid peroxidation inanimals and plants. Two types of the enzyme, 15-LOX-1 and 15-LOX-2, havebeen recognized in mammals to have different abilities in the peroxidationof arachidonic acid and linoleic acid. In mammalians, the critical role of thementioned enzymes and their metabolites, hydroxyoctadecadienoic acid(HODE), lipoxins and eoxins, in the formation of inflammation, sensitivities,atherosclerosis and some cancers has been demonstrated.Areas covered: This article reviews relevant publications and patents on 15-LOX inhibitors from the points of view of synthesis and biological activities.Herein, based on the chemical structure and pharmacophore moiety, 15-LOXinhibitors are categorized into heterocyclic, phenolic, allyl and allyloxyderivatives.Expert opinion: It is noteworthy that to date no pharmaceutical productfrom 15-LOX inhibitors has been approved for therapeutic usage. Recently,the role of 15-LOX-1 in obesity, by directly relating 15-LOX-1 expression withthe proliferation and hypertrophy of adipose cells, has been reported. Basedon the role 15-LOX plays in promoting cancer by amplifying PPARγtranscrip-tion activity, however, it can be claimed that 15-LOX inhibitors will bedeemed suitable as chemotherapy agents in the near futureen
languageEnglish
title15-Lipoxygenase inhibitors: A patent reviewen
typeJournal Paper
contenttypeExternal Fulltext
subject keywordsallyl benzenesen
subject keywordsallyloxy benzenesen
subject keywordseoxinen
subject keywordsheterocyclic compoundsen
subject keywordsHODEen
subject keywordsphenolic

compounds
en
journal titleExpert Opinion on Therapeutic Patentsfa
pages65-88
journal volume26
journal issue1
identifier linkhttps://profdoc.um.ac.ir/paper-abstract-1068400.html
identifier articleid1068400
  • درباره ما
نرم افزار کتابخانه دیجیتال "دی اسپیس" فارسی شده توسط یابش برای کتابخانه های ایرانی | تماس با یابش
DSpace software copyright © 2019-2022  DuraSpace